177 Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer
Radiology · 01.04.2026 · 319 (1)
DOI: 10.1148/radiol.252672 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Radiology, erschienen am 01.04.2026. Verfasst von Narjess Ayati und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, 390 Victoria St, Darlinghurst, NSW 2010, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Dipeptides, Radioisotopes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Lutetium 177 prostate-specific membrane antigen–617 SPECT/CT total tumor volume complete response at 6 weeks was associated with overall survival and may help guide early personalized treatment decisions in metastatic castration-resistant prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, 390 Victoria St, Darlinghurst, NSW 2010, Australia.
- St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
- Garvan Institute of Medical Research, Sydney, Australia.
- Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, Australia.
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
- Department of Medical Oncology, Bankstown-Lidcombe Hospital, Sydney, Australia.
ORCID-Profile: Narjess Ayati, Megan Crumbaker, Shalini Subramaniam, Anthony M Joshua, Ramin Alipour, Amir Iravani, Emran Askari, Matthias Eiber, Andrew Weickhardt, Sze-Ting Lee, Roslyn J Francis, David A Pattison, Andrew Nguyen, Michael S Hofman, Shahneen Sandhu, Julian C J van Oorschodt, Kathy Willowson, Shikha Sharma, Andrew J Martin, Hayley Thomas, Martin R Stockler, Ian D Davis, Louise Emmett
Zitieren
APA
Ayati, N., Papa, N., Crumbaker, M., Subramaniam, S., Joshua, A. M., Alipour, R., Iravani, A., Askari, E., Khan, S., Yadav, S., Eiber, M., Weickhardt, A., Lee, S. T., Ng, S., Francis, R. J., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., …, & Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group (2026). 177 Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Radiology, 319(1). https://doi.org/10.1148/radiol.252672
Vancouver
Ayati N, Papa N, Crumbaker M, Subramaniam S, Joshua AM, Alipour R, et al. 177 Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Radiology. 2026;319(1). doi:10.1148/radiol.252672
BibTeX
@article{Ayati2026,
author = {Ayati, Narjess and Papa, Nathan and Crumbaker, Megan and Subramaniam, Shalini and Joshua, Anthony M and Alipour, Ramin and Iravani, Amir and Askari, Emran and Khan, Sobia and Yadav, Surekha and Eiber, Matthias and Weickhardt, Andrew and Lee, Sze-Ting and Ng, Siobhan and Francis, Roslyn J and Goh, Jeffrey C and Pattison, David A and Tan, Thean Hsiang and Kirkwood, Ian D and Nguyen, Andrew and Hofman, Michael S and Sandhu, Shahneen and Hioki, Takanori and van Oorschodt, Julian C J and Devitt, Katrina and Willowson, Kathy and Sharma, Shikha and Stancu, Alexandru and Chauvie, Stephane and Wilson, Peter and Martin, Andrew J and Thomas, Hayley and Stockler, Martin R and Davis, Ian D and Emmett, Louise and Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group},
title = {177 Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer},
journal = {Radiology},
year = {2026},
volume = {319},
number = {1},
doi = {10.1148/radiol.252672}
}
EUVIMED